Hypervigilance critical for difficult-to-detect melanoma

Hypervigilance critical for difficult-to-detect melanoma

(HealthDay)—Monitoring patients at extreme risk with total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI) assists with early diagnosis of primary melanoma, according to a study published online June 25 in JAMA Dermatology.

Fergal J. Moloney, M.D., from the University of Sydney, and colleagues compared six-month full-body examination versus TBP in 311 (February 2006 to February 2011). Patients had either a of invasive melanoma and dysplastic nevus syndrome, a history of invasive melanoma and at least three first-degree or second-degree relatives with prior melanoma, a history of at least two primary invasive , or a CDKN2A or CDK4 gene mutation.

The researchers found that there were 75 primary melanomas detected over a median of 3.5 years of follow-up, including 14 at the baseline visit. TBP detected 38 percent, and 39 percent were detected with SDDI. Breslow thickness of >1 mm was seen in five melanomas, three of which were histologically desmoplastic, while the other two had nodular components. By year two, the cumulative risk of developing a novel primary melanoma was 12.7 percent, with new primary melanoma incidence during the final three years of follow-up half of that seen during the first two years (incidence density ratio, 0.43; P = 0.002).

"Hypervigilance for difficult-to-detect thick melanoma subtypes is crucial," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Risk of second primary melanoma up in pediatric patients

Jun 28, 2012

(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study ...

Stage III/IV melanoma patients at risk for new primaries

Dec 10, 2013

(HealthDay)—Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

11 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

21 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.